Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Inogen reported a quarterly loss of $0.20 per share, which is better than the Zacks Consensus Estimate of a loss of $0.22, and an improvement from a loss of $0.25 per share a year ago [1][2] - The company achieved an earnings surprise of +9.09% for the quarter, having surpassed consensus EPS estimates in all four of the last quarters [2] - Inogen's revenues for the quarter were $92.39 million, slightly missing the Zacks Consensus Estimate by 0.12%, but showing growth from $88.83 million year-over-year [3] Financial Performance - The company has consistently exceeded consensus revenue estimates three times over the last four quarters [3] - The current consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $89.4 million, and for the current fiscal year, it is -$0.95 on revenues of $356.5 million [8] Market Position - Inogen shares have declined approximately 12.1% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [4] - The Zacks Industry Rank places the Medical - Instruments sector in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [9] Future Outlook - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [4][5] - The estimate revisions trend for Inogen was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [7]